| Mass Balance Study of [14C] LPM3770164 in Healthy Participants (NCT07516899) | Luye Pharma Group Ltd. | 2026-04-30 |
| A Study of LY03015 in Healthy Chinese and Caucasian Adult Subjects (NCT07671833) | Luye Pharma Group Ltd. | 2026-04-15 |
| LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation (NCT07391566) | Luye Pharma Group Ltd. | 2026-03-31 |
| To Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Food Effects of LY03021 in Healthy Chinese Subjects (NCT07371065) | Luye Pharma Group Ltd. | 2025-10-28 |
| A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020 (NCT07230652) | Luye Pharma Group Ltd. | 2025-08-20 |
| A Food Effect Study of LY03020 in Healthy Subjects (NCT07292233) | Luye Pharma Group Ltd. | 2025-07-30 |
| A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017 (NCT06980207) | Luye Pharma Group Ltd. | 2025-05-01 |
| Effect of Food and Age on the Pharmacokinetics of LY03017 (NCT06793995) | Luye Pharma Group Ltd. | 2025-02-01 |
| Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia (NCT06731868) | Luye Pharma Group Ltd. | 2025-01-14 |
| Identify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART) (NCT07236476) | Luye Pharma Group Ltd. | 2024-10-09 |
| Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC (NCT06496048) | Luye Pharma Group Ltd. | 2024-09-14 |
| A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects (NCT06556966) | Luye Pharma Group Ltd. | 2024-08-19 |
| Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets (NCT06474650) | Luye Pharma Group Ltd. | 2024-07-31 |
| To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets (NCT06426485) | Luye Pharma Group Ltd. | 2024-05-30 |
| A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017 (NCT06388551) | Luye Pharma Group Ltd. | 2024-05-10 |
| First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors. (NCT06240546) | Luye Pharma Group Ltd. | 2024-03-12 |
| Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer (NCT06128837) | Luye Pharma Group Ltd. | 2024-03-03 |
| Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Orthopedic Surgery (NCT06467409) | Luye Pharma Group Ltd. | 2024-01-26 |
| Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects (NCT06216054) | Luye Pharma Group Ltd. | 2023-12-19 |
| Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h) (NCT05853341) | Luye Pharma Group Ltd. | 2023-05-02 |
| Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg (NCT05856630) | Luye Pharma Group Ltd. | 2023-05-01 |
| Comparative Efficacy, Safety, PK, and Immunogenicity Study (NCT05853354) | Luye Pharma Group Ltd. | 2023-04-05 |
| Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Abdominal Surgery (NCT06204120) | Luye Pharma Group Ltd. | 2022-11-25 |
| Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer (NCT06098599) | Luye Pharma Group Ltd. | 2022-05-17 |
| A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects (NCT05238701) | Luye Pharma Group Ltd. | 2022-02-25 |
| An Exploratory Study of LPM3480392 at Different Infusion Rates in Chinese Healthy Subjects (NCT05857449) | Luye Pharma Group Ltd. | 2021-11-08 |
| Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors (NCT04859569) | Luye Pharma Group Ltd. | 2021-04-30 |
| Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors (NCT05865925) | Luye Pharma Group Ltd. | 2021-04-22 |
| A Pharmacokinetic Similarity Study in Healthy Male Subjects to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of LY06006 Versus US-Prolia and EU-Prolia by Single-dose Subcutaneous Injection (NCT06095427) | Luye Pharma Group Ltd. | 2021-03-09 |
| A Dose-escalation Study of LPM3480392 in Chinese Healthy Subjects (NCT05862974) | Luye Pharma Group Ltd. | 2021-02-25 |
| Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX® (NCT05140512) | Luye Pharma Group Ltd. | 2021-02-04 |
| to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers (NCT04593511) | Luye Pharma Group Ltd. | 2021-02-02 |
| Relative Bioavailability of LY03010 Compared to Listed Drug (NCT04922593) | Luye Pharma Group Ltd. | 2021-01-13 |
| A Study to Evaluate LY06006 and Prolia in Healthy Adults (NCT04973722) | Luye Pharma Group Ltd. | 2020-12-09 |
| Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients (NCT04638491) | Luye Pharma Group Ltd. | 2020-11-24 |
| A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects (NCT04973735) | Luye Pharma Group Ltd. | 2020-11-10 |
| A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD） (NCT04572698) | Luye Pharma Group Ltd. | 2020-11-01 |
| Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX® (NCT05110170) | Luye Pharma Group Ltd. | 2020-10-15 |
| Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer (NCT04381910) | Luye Pharma Group Ltd. | 2020-09-28 |
| A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD (NCT04630860) | Luye Pharma Group Ltd. | 2020-07-07 |
| A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers (NCT04384666) | Luye Pharma Group Ltd. | 2020-06-02 |
| A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD (NCT04571164) | Luye Pharma Group Ltd. | 2020-05-11 |
| Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients (NCT04572685) | Luye Pharma Group Ltd. | 2020-01-22 |
| Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX® (NCT04563936) | Luye Pharma Group Ltd. | 2020-01-06 |
| A Study to Evaluate LY01011 and Xgeva® in Healthy Adults (NCT04198636) | Luye Pharma Group Ltd. | 2019-12-16 |
| A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture (NCT05060406) | Luye Pharma Group Ltd. | 2019-06-30 |
| A Relative Bioavailability Food Effect Study of LY03005 (NCT03822065) | Luye Pharma Group Ltd. | 2019-01-16 |
| A Study Evaluating the Safety, Tolerability of LPM3480226 Tablets in Patients With Advanced Solid Tumors (NCT03844438) | Luye Pharma Group Ltd. | 2018-12-18 |
| A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients (NCT03751488) | Luye Pharma Group Ltd. | 2018-12-12 |
| A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD) (NCT04853407) | Luye Pharma Group Ltd. | 2018-12-05 |
| A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro (NCT03733561) | Luye Pharma Group Ltd. | 2018-11-09 |
| A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients (NCT04629404) | Luye Pharma Group Ltd. | 2018-11-05 |
| A Study of LY03005 vs Pristiq (NCT03733574) | Luye Pharma Group Ltd. | 2018-06-19 |
| A Study to Evaluate the Denosumab in Healthy Adults (NCT03427853) | Luye Pharma Group Ltd. | 2018-01-10 |
| A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer (NCT03450109) | Luye Pharma Group Ltd. | 2017-12-22 |
| Relative Bioavailability (RBA) Study of LY03005 vs Pristiq® (NCT03357796) | Luye Pharma Group Ltd. | 2017-11-27 |
| A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease (NCT04045678) | Luye Pharma Group Ltd. | 2017-10-10 |